PPAR gamma gene - A review

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 9, Issue 1, 2015, Pages 46-50

  Janani, C ^a   Ranjitha Kumari, B D ^a  

^a BHARATHIDASAN UNIVERSITY   (India)

Author keywords

Glucose homeostasis; Inflammatory response; Insulin sensitivity; PPAR gamma; Transformation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HORMONE RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 3; ROSIGLITAZONE; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; LIGAND;

ATHEROSCLEROSIS; BROWN ADIPOSE TISSUE; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENE ISOLATION; HUMAN; INSULIN BINDING; INSULIN SENSITIVITY; LIPID METABOLISM; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; WHITE ADIPOSE TISSUE; ADIPOCYTE; ADIPOSE TISSUE; AGONISTS; DIABETES MELLITUS, TYPE 2; GENETIC TRANSCRIPTION; GENETICS; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; INSULIN RESISTANCE; METABOLISM; MOLECULARLY TARGETED THERAPY;

ADIPOCYTES; ADIPOSE TISSUE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; LIGANDS; MOLECULAR TARGETED THERAPY; PPAR ALPHA; PPAR GAMMA; TRANSCRIPTION, GENETIC;

EID: 84920718031     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2014.09.015     Document Type: Review

References (76)

1. F.S. Anthony, E. Braunwald, D.L. Kasper, H.L. Hauser, D.L. Longo, and J.L. Jomeson Harrison's Principles of Internal Medicine 17th ed. 2008 McGraw Hill Publication 2275
2. R.A. DeFronzo Pathogenesis of type 2 diabetes mellitus Med Clin N Am 88 2004 787 835
3. G.M. Reaven Role of insulin resistance in human disease Diabetes 3 1988 1595 1607
4. R.H. Unger Lipotoxicity in the pathogenesis of obesity dependent NIDDM: genetic and clinical implications Diabetes 44 1995 863 870
5. G.B. Moore, H. Chapman, J.C. Holder, C.A. Lister, V. Piercy, and S.A. Smith Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice Biochem Biophys Res Commun 286 2001 735 741
6. B.M. Spiegelman PPAR-gamma: adipogenic regulator and thiazolidinedione receptor Diabetes 47 1998 507 514
7. M. Shimabukuro, Y.T. Zhou, Y. Lee, and R.H. Unger Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats J Biol Chem 273 1998 3547 3550
8. D.T. Finegood, M.D. Mcarthur, D. Kojwang, M.J. Thomas, B.G. Topp, and T. Leonard β-Cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death Diabetes 50 2001 1021 1029
9. C.L. Brand, J. Sturis, C.F. Gotfredsen, J. Fleckner, C. Fledelius, and B.F. Hansen Dual PPARa/g activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats Am J Physiol 284 2003 E841 E854
10. L. Pickavance, P.S. Widdowson, J.R. Foster, G. Williams, and J.P. Wilding Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and b-cell apoptosis in the pancreas of the Zucker diabetic fatty rat Int J Exp Pathol 84 2003 83 89
11. K. Yajima, H. Hirose, H. Fujita, Y. Seto, H. Fujita, and K. Ukeda Combination therapy with PPARg and PPARa agonists increases glucose-stimulated insulin secretion in db/db mice Am J Physiol Endocrinol Metab 284 2003 E966 E971
12. A.D. Mooradian, J. Chehade, and J.E. Thurman The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus Treat Endocrinol 1 2002 13 20
13. C. Fogg, R. Kasliwal, and S.A. Shakir Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study Drug Saf 32 2009 229 237
14. J. Berger, and D.E. Moller The mechanisms of action of PPARs Annu Rev Med 53 2002 409 435
15. E. Boitier, J.C. Gautier, and R. Roberts Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease Comp Hepatol 2 1 2003 3
16. A. Rogue, C. Lambert, R. Josse, S. Antherieu, C. Spire, and N. Claude Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes PLoS ONE 6 4 2001 e18816
17. A. Rogue, C. Spire, M. Brun, N. Claude, and A. Guillouzo Gene expression changes induced by PPAR gamma agonists in animal and human liver PPAR Res 2010 2010 325183
18. T.M. Willson, P.J. Brown, D.D. Sternbach, and B.R. Henke The PPARs: from orphan receptors to drug discovery J Med Chem 43 2000 527 550
19. E. Hu, P. Tontonoz, and B. Spiegelman Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha Proc Natl Acad Sci U S A 92 1995 9856 9860
20. K. Yamanouchi, A. Ban, S. Shibata, T. Hosoyama, Y. Murakami, and M. Nishihara Both PPAR gamma and C/EBPalpha are sufficient to induce transdifferentiation of goat fetal myoblasts into adipocytes J Reprod Dev 53 2007 563 572
21. S.A. Kliewer, S.S. Sundseth, S.A. Jones, P.J. Brown, G.B. Wisely, and C.S. Koble Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma Proc Natl Acad Sci U S A 94 9 1997 4318 4323
22. S.H. Sheu, T. Kaya, D.J. Waxman, and S. Vajda Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping Biochemistry (Mosc) 44 4 2005 1193 1209
23. M. Lehrke, and M. Lazar The many faces of PPARγ Cell 123 2005 993 999
24. G. Medina-Gomez, S. Gray, and A. Vidal-Puig Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPAR gamma) and PPAR gamma coactivator-1 (PGC1) Public Health Nutr 10 2007 1132 1137
25. J.N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions Prog Lipid Res 45 2 2006 120 159
26. D. Ren, T.N. Collingwood, E.J. Rebar, A.P. Wolffe, and H.S. Camp PPAR gamma knockdown by engineered transcription factors: exogenous PPAR gamma 2 but not PPAR gamma 1 reactivates adipogenesis Genes Dev 16 1 2002 27 32
27. A. Werman, A. Hollenberg, G. Solanes, C. Bjorbaek, A.J. Vidal-Puig, and J.S. Flier Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPAR gamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin J Biol Chem 272 32 1997 20230 20235
28. G. Medina-Gomez, S.L. Gray, L. Yetukuri, K. Shimomura, S. Virtue, and M. Campbell PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism PLoS Genet 3 4 2007 64
29. U. Kintscher, and R.E. Law PPARγ mediated insulin sensitization: the importance of fat versus muscle Am J Physiol Endocrinol Metab 288 2 2005 E287 E291
30. N. Marx, T. Bourcier, G.K. Sukhova, P. Libby, and J. Plutzky PPAR gamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPAR gamma as a potential mediator in vascular disease Arterioscler Thromb Vasc Biol 19 3 1999 546 551
31. S. Sethi, O. Ziouzenkova, H. Ni, D.D. Wagner, J. Plutzky, and T.N. Mayadas Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha Blood 100 4 2002 1340 1346
32. A. Margeli, G. Kouraklis, and S. Theocharis Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis Angiogenesis 6 3 2003 165 169
33. D. Panigrahy, S. Huang, M.W. Kieran, and A. Kaipainen PPAR gamma as a therapeutic target for tumor angiogenesis and metastasis Cancer Biol Ther 4 7 2005 687 693
34. M. Heim, J. Johnson, F. Boess, I. Bendik, P. Weber, and W. Hunziker Phytanic acid, a natural peroxisome proliferator-activated receptor (PPAR) agonist, regulates glucose metabolism in rat primary hepatocytes FASEB J 16 7 2002 718 720
35. B. Qin, M. Nagasaki, M. Ren, G. Bajotto, Y. Oshida, and Y. Sato Cinnamon extract (traditional herb) potentiates in vivo insulin-regulated glucose utilization via enhancing insulin signaling in rats Diabetes Res Clin Pract 62 3 2003 139 148
36. E. Elstner, C. Muller, K. Koshizuka, E.A. Williamson, D. Park, and H. Asou Ligands for peroxisome proliferator activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice Proc Natl Acad Sci U S A 95 15 1998 8806 8811
37. M.H. Tan Current treatment of insulin resistance in type 2 diabetes mellitus Int J Clin Pract Suppl 113 2000 54 62
38. M.A. Deeg, and M.H. Tan Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins and apolipoproteins in head-to-head randomized clinical studies PPAR Res 2008 2008 520465:1-6
39. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J Biol Chem 270 1995 12953 12956
40. H. Yki-Jarvinen Thiazolidinediones N Engl J Med 351 2004 1106 1118
41. R. Eldor, R.A. DeFronzo, and M. Abdul-Gani In vivo actions of peroxisome proliferator-activated receptors Diabetes Care 36 Suppl. 2 2013
42. A. Gastaldelli, Y. Miyazaki, and M. Pettiti The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes J Clin Endocrinol Metab 1 2006 806 812
43. A. Gastaldelli, Y. Miyazaki, and A. Mahankali The effect of pioglitazone on the liver: role of adiponectin Diabetes Care 29 2006 2275 2281
44. R.A. DeFronzo Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 2009 773 795
45. Y. Miyazaki, A. Mahankali, and M. Matsuda Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone Diabetes Care 4 2001 710 719
46. Y. Miyazaki, and R.A. DeFronzo Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients Diabetes Obes Metab 10 2008 1204 1211
47. R.A. DeFronzo Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 Diabetologia 53 2010 1270 1287
48. H. Bays, L. Mandarino, and R.A. DeFronzo Role of the adipocyte, free fatty acids and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator activated receptor agonists provide a rational therapeutic approach J Clin Endocrinol Metab 89 2004 463 478
49. H.E. Bays, J.M. Gonzalez-Campoy, and G.A. Bray Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity Expert Rev Cardiovasc Ther 6 2008 343 368
50. Y. Miyazaki, H. He, L.J. Mandarino, and R.A. DeFronzo Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients Diabetes 52 2003 1943 1950
51. D.K. Coletta, A. Sriwijitkamol, and E. Wajcberg Pioglitazone stimulates AMP activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomized trial Diabetologia 52 2009 723 732
52. W.G.C.G. McDonald, S.L. Cole, D.D. Holewa, A.S. Brightwell-Conrad, R.F. Kletzien, and J.R. Colca Identification of a mitochondrial target of thiazolidinediones (mTOT) Diabetes 61 Suppl. 1 2012 A28
53. V.J. Colca Jr., W.J. Adams, J. Liang, R. Zhou, and D.G. Orloff Clinical proof of concepts with a prototype mTOT modulating insulin sensitizer Diabetes 61 Suppl. 1 2012 A246
54. A. Krishnaswami, S. Ravi-Kumar, and J.M. Lewis Thiazolidinediones: a 2010 perspective Perm J 14 3 2010 64 72
55. B. Grygiel-Gorniak Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review Nutr J 13 2014 17
56. M. Arevalo-Turrubiarte, L. Gonzalez-Davalos, A. Yabuta, J.D. Garza, J.L. Davalos, and O. Mora Effect of 2,4-thiazolidinedione on limousin cattle growth and on muscle and adipose tissue metabolism PPAR Res 2012 2012 891841:1-8
57. G.J. Hausman, S.P. Poulos, T.D. Pringle, and M.J. Azain The influence of thiazolidinediones on adipogenesis in vitro and in vivo: potential modifiers of intramuscular adipose tissue deposition in meat animals J Anim Sci 86 14 2008 E236 E243
58. M. Bionaz, G.J. Hausman, J.J. Loor, and S. Mandard Physiological and nutritional roles of PPAR across species PPAR Res 2013 1 3
59. J. Lin, C. Handschin, and B.M. Spiegelman Metabolic control through the PGC-1 family of transcription coactivators Cell Metab 1 2005 361 370
60. H. Esterbauer, H. Oberkofler, F. Krempler, and W. Patsch Human peroxisome proliferator activated receptor gamma coactivator 1 (PPAR GAMMAC1) gene: cDNA sequence, genomic organization, chromosomal localization and tissue expression Genomics 62 1999 98 102
61. B.M. Spiegelman Transcriptional control of mitochondrial energy metabolism through the PGC1 coactivators Novartis Found Symp 287 2007 60 63
62. A.L. Hevener, W. He, Y. Barak, J. Le, G. Bandyopadhyay, and P. Olson Muscle specific PPAR gamma deletion causes insulin resistance Nat Med 9 2003 1491 1497
63. N.K. Verma, J. Singh, and C.S. Dey PPAR-c expression modulates insulin sensitivity in C2C12 skeletal muscle cells Br J Pharmacol 143 2004 1006 1013
64. R.W. Whitcomb, and A.R. Saltiel Thiazolidinediones Expert Opin Invest Drug 4 1995 1299 1309
65. W.S. Yang, C.Y. Jeng, T.J. Wu, S. Tanaka, T. Funahashi, and Y. Matsuzawa Synthetic peroxisome proliferator-activated receptor-agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients Diabetes Care 25 2002 376 380
66. B.A. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr Rev 20 1999 649 688
67. A. Apostoli, and C.J. Nicol PPAR medicines and human disease: the ABCs of it all PPAR Res 2012 2012 10.1155/2012/504918
68. M. Menendez-Gutierrez, T. Roszer, and M. Ricote Biology and therapeutic applications of peroxisome proliferator-activated receptors Curr Top Med Chem 12 2012 548 584
69. M.U. Imam, M. Ismail, H. Ithnin, Z. Tubesha, and A.R. Omar Effects of germinated brown rice and its bioactive compounds on the expression of the peroxisome proliferator-activated receptor gamma gene Nutrients 5 2013 468 477
70. A. Ban, K. Yamanouchi, T. Matsuwaki, and M. Nishihara In vivo gene transfer of PPAR gamma is insufficient to induce adipogenesis in skeletal muscle J Vet Med Sci 70 8 2008 761 767
71. W. He, Y. Barak, A. Hevener, P. Olson, D. Liao, and J. Le Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle Proc Natl Acad Sci U S A 100 2003 15712 15717
72. H. Koutnikova, T.A. Cock, M. Watanabe, S.M. Houten, M.F. Champy, and A. Dierich Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice Proc Natl Acad Sci U S A 100 2003 14457 14462
73. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research R. Saxena, B.F. Voight, V. Lyssenko, N.P. Burtt, and P.I. de Bakker Genome wide association analysis identifies loci for type 2 diabetes and triglyceride levels Science 316 2007 1331 1336
74. Y.R. Liu, T.M. Hu, T.H. Lan, H.J. Chiu, Y.H. Chang, and S.F. Chen Association of the PPAR-γ gene with altered glucose levels and psychosis profile in schizophrenia patients exposed to antipsychotics Psychiatry Investig 11 2 2014 179 185
75. R. Rani, and V.K. Kansal Study on cow ghee versus soybean oil on 7,12-dimethylbenz (a)-anthracene induced mammary Indian J Med Res 133 5 2011 497 503
76. R.J. Perera, E.G. Marcusson, S. Koo, X. Kang, Y. Kim, and N. White Identification of novel PPARγ target genes in primary human adipocytes Gene 369 2006 90 99